cagrilintide news 2025 Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes CagriSema Achieves 22.7% Weight Loss
Description
That gap between expectation and reality is worth understanding, because it points to something important about how mood act
Semaglutides phase 2 trial produced roughly 13% weight loss and clear steatohepatitis resolution yet failed to move fibrosis significantly at 72 weeks a reminder that fibrosis remodeling lags behind fat and inflammation and may require more time or additional mechanisms
Furthermore, standard sterile water lacks this preservative and must be discarded immediately after a single opening
The most commonly observed side effects include mild injection-site irritation and nausea, which subside within the first week or two, especially at lower doses
This prevents contamination
